Viral miRNA-mediated activation of hyaluronan production as a drug target against COVID-19

被引：0
|
作者：
Shuai Yang [1 ,2 ]
Lu Chen [1 ,2 ]
Ying Tong [1 ,2 ]
Wenqiang Yu [1 ,2 ]
机构：
[1] Laboratory of RNA Epigenetics, Institutes of Biomedical Sciences & Shanghai Public Health Clinical Center & Department of General Surgery, Huashan Hospital, Cancer Metastasis Institute, Shanghai Medical College, Fudan University
[2] Shanghai Key Laboratory of Medical Epigenetics
来源：
ActaPharmaceuticaSinicaB | 2022年 / 12卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The global coronavirus disease 2019(COVID-19) pandemic has caused more than 6.1 million deaths until March 24, 2022, as reported by the World Health Organization(WHO). Recently,breakthrough infections have appeared in individuals fully vaccinated against SARS-Co V-21, which could be attributed to the rapid mutation of the RNA virus2. Currently, following the Delta variant, the Omicron variant of SARS-Co V-2 is increasingly becoming the dominant epidemic strain in the world.
引用
收藏
页码：3195 / 3197
页数：3
相关论文
共 50 条
  • [31] Drug repositioning against COVID-19: a first line treatment
    Bibi, Nousheen
    Farid, Ayesha
    Gul, Sana
    Ali, Johar
    Amin, Farhat
    Kalathiya, Umesh
    Hupp, Ted
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (23): : 12812 - 12826
  • [32] Molecules against COVID-19: An in Silico Approach for Drug Development
    Rhythm Bharti
    Sandeep Kumar Shukla
    JournalofElectronicScienceandTechnology, 2021, 19 (01) : 14 - 24
  • [33] Drug repurposing against COVID-19: focus on anticancer agents
    Ciliberto, Gennaro
    Mancini, Rita
    Paggi, Marco G.
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
  • [34] Drug repurposing against COVID-19: focus on anticancer agents
    Gennaro Ciliberto
    Rita Mancini
    Marco G. Paggi
    Journal of Experimental & Clinical Cancer Research, 39
  • [35] The contact activation system as a potential therapeutic target in patients with COVID-19
    Shatzel, Joseph J.
    DeLoughery, Emma P.
    Lorentz, Christina U.
    Tucker, Erik I.
    Aslan, Joseph E.
    Hinds, Monica T.
    Gailani, David
    Weitz, Jeffrey I.
    McCarty, Owen J. T.
    Gruber, Andras
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2020, 4 (04) : 500 - 505
  • [36] CSF3 Is a Potential Drug Target for the Treatment of COVID-19
    Fang, Chao
    Mei, Jie
    Tian, Huixiang
    Liou, Yu-Ligh
    Rong, Dingchao
    Zhang, Wei
    Liao, Qianjin
    Wu, Nayiyuan
    FRONTIERS IN PHYSIOLOGY, 2021, 11
  • [37] Diacerein: A potential multi-target therapeutic drug for COVID-19
    de Oliveira, Pedro Goncalves
    Termini, Lara
    Durigon, Edison Luiz
    Lepique, Ana Paula
    Sposito, Andrei C.
    Boccardo, Enrique
    MEDICAL HYPOTHESES, 2020, 144
  • [38] Allosteric Site of ACE-2 as a Drug Target for COVID-19
    Dutta, Kunal
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2022, 5 (03) : 179 - 182
  • [39] The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target
    Abu-Farha, Mohamed
    Thanaraj, Thangavel Alphonse
    Qaddoumi, Mohammad G.
    Hashem, Anwar
    Abubaker, Jehad
    Al-Mulla, Fahd
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (10)
  • [40] Production of equine sera as a potential immunotherapy against COVID-19
    Cepeda, Mariana, V
    Jimenez, Juan C.
    Pujol, Flor H.
    Rangel, Hector R.
    Bello, Carlos
    Cubillan, Jose
    Serrano, Maria L.
    Chacon, Tony
    Saba, Antonietta
    Lopez, Miguel A.
    Rodriguez-Acosta, Alexis
    INVESTIGACION CLINICA, 2021, 62 : 3 - 17
12345